Q-omics provides the consensus-scored SPIRE1 profile across patient tissues and cancer cell-line models. SPIRE1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SPIRE1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SPIRE1 RNA expression shows 19,274 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where SPIRE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPIRE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPIRE1 survival associations across molecular data types. SPIRE1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPIRE1 RNA expression–survival associations across cancer types. High SPIRE1 expression shows unfavorable associations in MESO, STAD, UVM and UCEC, but favorable associations in KIRC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SPIRE1 RNA expression.
This table summarizes SPIRE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPIRE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPIRE1 shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRC, KICH, COAD and CHOL. The HNSC box plot shows higher SPIRE1 RNA expression in tumor versus normal tissue (log2 FC = +1.341, t-test p < 0.001).
This table shows molecular features associated with SPIRE1 in patient tissues and cancer cell lines. In patient samples, SPIRE1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPIRE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
